NVAX News

Novavax Announces Entering into a License Agreement with Pfizer

85 years of bold discovery: Texas Biomed marks milestone anniversary

Halo Pharma Enhances Manufacturing Capabilities with Macro-Pactor® Investment

New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use

Novavax to Participate in Jefferies London Healthcare Conference

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Novavax Announces Progress on Sanofi Agreement